A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Réunion Island.
Adrenal Cortex Hormones
/ administration & dosage
Aged
Azithromycin
/ administration & dosage
COVID-19
/ virology
Drug Therapy, Combination
Female
Hospitalization
Humans
Hydroxychloroquine
/ administration & dosage
Intensive Care Units
Kaplan-Meier Estimate
Male
Middle Aged
Retrospective Studies
Reunion
SARS-CoV-2
/ isolation & purification
COVID-19 Drug Treatment
Azithromycin
COVID-19
Corticosteroids
Hydroxychloroquine
SARS-CoV-2
Journal
Journal of global antimicrobial resistance
ISSN: 2213-7173
Titre abrégé: J Glob Antimicrob Resist
Pays: Netherlands
ID NLM: 101622459
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
11
06
2020
revised:
22
07
2020
accepted:
01
08
2020
pubmed:
24
8
2020
medline:
20
1
2021
entrez:
24
8
2020
Statut:
ppublish
Résumé
This study aimed to evaluate the prognosis of COVID-19 patients in Reunion Island, with a particular focus on the management of patients with hypoxemic pneumonia. This retrospective observational study was conducted from 11 March to 17 April 2020 at the only hospital authorized to manage patients with COVID-19 in Reunion Island. Over the study period, 164 out of 398 patients (41.2%) infected with COVID-19 were admitted to Félix Guyon University Hospital. Of these, 36 (22%) developed hypoxemic pneumonia. Patients with hypoxemic pneumonia were aged 66 [56-77] years, 69% were male and 33% had hypertension. Ten patients (27.8%) were hospitalized in intensive care unit (ICU). Hydroxychloroquine/azithromycin treatment was associated with a lower ICU admission rate (P=0.008). None of the 6 patients treated with corticosteroids were hospitalized in ICU (P=0.16). There were no deaths at follow up (minimum 80 days). Despite the risk profile of COVID-19 patients with severe hypoxemic pneumonia, the mortality rate of the disease in Reunion Island was 0%. This may be due to the care bundle used in our hospital (early hospitalisation, treatment with hydroxychloroquine/azithromycin and/or corticosteroids, non-invasive respiratory support, etc).
Sections du résumé
BACKGROUND
This study aimed to evaluate the prognosis of COVID-19 patients in Reunion Island, with a particular focus on the management of patients with hypoxemic pneumonia.
METHODS
This retrospective observational study was conducted from 11 March to 17 April 2020 at the only hospital authorized to manage patients with COVID-19 in Reunion Island.
RESULTS
Over the study period, 164 out of 398 patients (41.2%) infected with COVID-19 were admitted to Félix Guyon University Hospital. Of these, 36 (22%) developed hypoxemic pneumonia. Patients with hypoxemic pneumonia were aged 66 [56-77] years, 69% were male and 33% had hypertension. Ten patients (27.8%) were hospitalized in intensive care unit (ICU). Hydroxychloroquine/azithromycin treatment was associated with a lower ICU admission rate (P=0.008). None of the 6 patients treated with corticosteroids were hospitalized in ICU (P=0.16). There were no deaths at follow up (minimum 80 days).
CONCLUSIONS
Despite the risk profile of COVID-19 patients with severe hypoxemic pneumonia, the mortality rate of the disease in Reunion Island was 0%. This may be due to the care bundle used in our hospital (early hospitalisation, treatment with hydroxychloroquine/azithromycin and/or corticosteroids, non-invasive respiratory support, etc).
Identifiants
pubmed: 32828896
pii: S2213-7165(20)30206-X
doi: 10.1016/j.jgar.2020.08.001
pmc: PMC7439827
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Hydroxychloroquine
4QWG6N8QKH
Azithromycin
83905-01-5
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-3Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Travel Med Infect Dis. 2020 Mar - Apr;34:101663
pubmed: 32289548
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
N Engl J Med. 2020 Jul 17;:
pubmed: 32678530